CoChat

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy. However, no modern studies have evaluated subjective and autonomic effects of different and pharmaceutically well-defined doses of LSD. We used a double-blind, randomized, placebo-controlled, crossover design in 16 healthy subjects (eight women, eight men) who underwent six 25 h sessions and received placebo, LSD (25, 50, 100, and 200 µg), and 200 µg LSD 1 h after administration of the serotonin 5-hydroxytryptamine-2A (5-HT 2A ) receptor antagonist ketanserin (40 mg). Test days were separated by at least 10 days. Outcome measures included self-rating scales that evaluated subjective effects, autonomic effects, adverse effects, plasma brain-derived neurotrophic factor levels, and pharmacokinetics up to 24 h. The pharmacokinetic-subjective response relationship was evaluated. LSD showed dose-proportional pharmacokinetics and first-order elimination and dose-dependently induced subjective responses starting at the 25 µg dose. A ceiling effect was observed for good drug effects at 100 µg. The 200 µg dose of LSD induced greater ego dissolution than the 100 µg dose and induced significant anxiety. The average duration of subjective effects increased from 6.7 to 11 h with increasing doses of 25–200 µg. LSD moderately increased blood pressure and heart rate. Ketanserin effectively prevented the response to 200 µg LSD. The LSD dose–response curve showed a ceiling effect for subjective good effects, and ego dissolution and anxiety increased further at a dose above 100 µg. These results may assist with dose finding for future LSD research. The full psychedelic effects of LSD are primarily mediated by serotonin 5-HT 2A receptor activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41386-020-00883-6

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Acute subjective effects of lysergic acid diethylamide (LSD) over time. LSD (25–200 µg) or placebo was administered at t = 0 h. Ketanserin (K) or placebo was administered at t = −1 h. LSD dose-dependently induced good drug effects, with a maximum effect reached at the 100 µg dose. The 200 µg dose of LSD did not further increase good drug effects or drug liking compared with the 100 µg dose, but it further increased ego dissolution compared with the 100 µg dose. Ketanserin markedly reduced the response to the high 200 µg dose of LSD approximately to the levels of the 25 µg and delayed the remaining small good drug effect and drug liking response compared with LSD alone. The data are expressed as the mean ± SEM percentage of maximally possible scale scores in 16 subjects. The corresponding maximal responses and statistics are shown in Supplementary Table S2.
Fig. 1 Acute subjective effects of lysergic acid diethylamide (LSD) over time. LSD (25–200 µg) or placebo was administered at t = 0 h. Ketanserin (K) or placebo was administered at t = −1 h. LSD dose-dependently induced good drug effects, with a maximum effect reached at the 100 µg dose. The 200 µg dose of LSD did not further increase good drug effects or drug liking compared with the 100 µg dose, but it further increased ego dissolution compared with the 100 µg dose. Ketanserin markedly reduced the response to the high 200 µg dose of LSD approximately to the levels of the 25 µg and delayed the remaining small good drug effect and drug liking response compared with LSD alone. The data are expressed as the mean ± SEM percentage of maximally possible scale scores in 16 subjects. The corresponding maximal responses and statistics are shown in Supplementary Table S2.CC BY · PubMed Central
Fig. 2 Acute alterations of mind on the 5 Dimensions of Altered States of Consciousness (5D-ASC) Scale. All lysergic acid diethylamide (LSD) doses (25–200 µg) increased “oceanic boundlessness” and “visionary restructuralization.” Only the 50, 100, and 200 µg doses of LSD significantly influenced “anxious ego dissolution.” The dose–response curve showed a ceiling effect for oceanic boundlessness and visionary restructuralization ratings at the 100 µg dose. In contrast, ratings of anxious ego dissolution further increased at the 200 µg dose compared with the 100 µg dose. Additionally, only the 200 µg dose and not the 100 µg dose induced significant anxiety. Ketanserin markedly reduced the response to the highest LSD dose (200 μg) approximately to the level of the 25 µg dose. Placebo scores were too low for visualization. The data are expressed as the mean ± SEM percentage of maximally possible scale scores in 16 subjects. Statistics are shown in Supplementary Table S2.
Fig. 2 Acute alterations of mind on the 5 Dimensions of Altered States of Consciousness (5D-ASC) Scale. All lysergic acid diethylamide (LSD) doses (25–200 µg) increased “oceanic boundlessness” and “visionary restructuralization.” Only the 50, 100, and 200 µg doses of LSD significantly influenced “anxious ego dissolution.” The dose–response curve showed a ceiling effect for oceanic boundlessness and visionary restructuralization ratings at the 100 µg dose. In contrast, ratings of anxious ego dissolution further increased at the 200 µg dose compared with the 100 µg dose. Additionally, only the 200 µg dose and not the 100 µg dose induced significant anxiety. Ketanserin markedly reduced the response to the highest LSD dose (200 μg) approximately to the level of the 25 µg dose. Placebo scores were too low for visualization. The data are expressed as the mean ± SEM percentage of maximally possible scale scores in 16 subjects. Statistics are shown in Supplementary Table S2.CC BY · PubMed Central
Fig. 3 Acute autonomic effects. Doses of 50, 100, and 200 µg lysergic acid diethylamide (LSD) similarly increased systolic blood pressure compared with placebo. The 100 and 200 µg doses similarly increased diastolic blood pressure and heart rate compared with placebo. Ketanserin (K) transiently decreased blood pressure, heart rate, and body temperature, with a delayed increase to the levels that were reached after the administration of LSD alone. LSD (25–200 µg) or placebo was administered at t = 0 h. Ketanserin (K) or placebo was administered at t = −1 h. The data are expressed as the mean ± SEM in 16 subjects. Maximal effects and statistics are shown in Supplementary Table S2.
Fig. 3 Acute autonomic effects. Doses of 50, 100, and 200 µg lysergic acid diethylamide (LSD) similarly increased systolic blood pressure compared with placebo. The 100 and 200 µg doses similarly increased diastolic blood pressure and heart rate compared with placebo. Ketanserin (K) transiently decreased blood pressure, heart rate, and body temperature, with a delayed increase to the levels that were reached after the administration of LSD alone. LSD (25–200 µg) or placebo was administered at t = 0 h. Ketanserin (K) or placebo was administered at t = −1 h. The data are expressed as the mean ± SEM in 16 subjects. Maximal effects and statistics are shown in Supplementary Table S2.CC BY · PubMed Central
Fig. 4 Pharmacokinetics and subjective effects of lysergic acid diethylamide (LSD). a Plasma LSD concentration-time curves for 25, 50, 100, and 200 µg doses of LSD. b–e LSD effect-time curves for Visual Analog Scale ratings (0–100%) of (b) “any drug effect,” (c) “good drug effect,” (d) “bad drug effect,” and (e) “ego dissolution.” LSD administration resulted in dose-proportional increases in plasma concentrations of LSD, but subjective good drug effects reached a ceiling at the 100 μg dose and did not further increase at the 200 µg dose. In contrast, bad drug effects and ego dissolution increased further at the 200 µg dose compared with 100 µg. Therefore, LSD doses higher than 100 µg produced no further increases in good drug effects but more ego dissolution and anxiety. The data are expressed as the mean ± SEM in 16 subjects. LSD was administered at t = 0 h. The lines represent the means of the individual pharmacokinetic–pharmacodynamic (subjective effect) model predictions.
Fig. 4 Pharmacokinetics and subjective effects of lysergic acid diethylamide (LSD). a Plasma LSD concentration-time curves for 25, 50, 100, and 200 µg doses of LSD. b–e LSD effect-time curves for Visual Analog Scale ratings (0–100%) of (b) “any drug effect,” (c) “good drug effect,” (d) “bad drug effect,” and (e) “ego dissolution.” LSD administration resulted in dose-proportional increases in plasma concentrations of LSD, but subjective good drug effects reached a ceiling at the 100 μg dose and did not further increase at the 200 µg dose. In contrast, bad drug effects and ego dissolution increased further at the 200 µg dose compared with 100 µg. Therefore, LSD doses higher than 100 µg produced no further increases in good drug effects but more ego dissolution and anxiety. The data are expressed as the mean ± SEM in 16 subjects. LSD was administered at t = 0 h. The lines represent the means of the individual pharmacokinetic–pharmacodynamic (subjective effect) model predictions.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Passie T. The science of microdosing psychedelics. London: Psychedelic Press; 2019.

Cited by

See all 257

Metadata

Authors
Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E.
Affiliations
University of Basel (CH)
Corresponding author
Liechti, Matthias E.
Venue
Neuropsychopharmacology
Published
2020-10-15
Volume
46
Issue
3
Pages
537-544
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W3093375227
Cited by
245
References
42
Citations by year
2026: 27 · 2025: 57 · 2024: 44 · 2023: 34 · 2022: 49 · 2021: 32 · 2020: 2
FWCI
11.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (32003B_185111)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
Keywords
lysergic acid diethylamide, LSD, dose-response relationship, 5-HT2A receptor, ketanserin, ego dissolution, anxiety, subjective effects, autonomic effects, blood pressure, heart rate, brain-derived neurotrophic factor, pharmacokinetics, ceiling effect, psychedelic effects, dose-finding
MeSH terms
Double-Blind Method, Female, Hallucinogens, Humans, Ketanserin, Lysergic Acid Diethylamide, Male, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. https://app.cochat.ai/papers/10.1038/s41386-020-00883-6
The paper
Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2021). Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. https://doi.org/10.1038/s41386-020-00883-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.